Osimertinib (VIII, Figure 2) is an FDA-approved indole-containing drug to treat NSCLC as an EGFR inhibitor; however, it exhibits severe adverse effects and cardiotoxicity at high doses and is of low selectivity towards EGFR [31]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.